Core Viewpoint - 康哲药业's subsidiary, 德镁医药, is applying for an independent listing on the Hong Kong Stock Exchange, focusing on innovative pharmaceuticals for skin health [1] Group 1: Company Developments - 德镁医药 has received approval from the National Medical Products Administration (NMPA) for its innovative oral JAK1 inhibitor, povorcitinib, to be included in the list of breakthrough therapies [1] - The proposed indication for povorcitinib is for adult patients with non-segmental vitiligo, which is expected to accelerate the product's research and review process [1] Group 2: Market Implications - The listing on the Hong Kong Stock Exchange is scheduled for April 22, 2025, indicating a strategic move to enhance capital and visibility in the market [1]
康哲药业(00867.HK)创新药口服小分子JAK1抑制剂”Povorcitinib“纳入突破性治疗品种名单